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Abstract	  
The	  chromatin	  environment	  is	  essential	  for	  the	  correct	  specification	  and	  preservation	  of	  cell	  identity	  
through	   modulation	   and	   maintenance	   of	   transcription	   patterns.	   Many	   chromatin	   regulators	   are	  
required	  for	  development,	  stem	  cell	  maintenance	  and	  differentiation.	  Here,	  we	  review	  the	  roles	  of	  
the	  Polycomb	  repressive	  complexes,	  PRC1	  and	  PRC2,	  and	  the	  HDAC1/2-­‐containing	  complexes,	  NuRD,	  
Sin3	  and	  CoREST,	   in	   stem	  cells,	  development	  and	  cancer	  as	  well	   as	   the	  ongoing	  efforts	   to	  develop	  
therapies	  targeting	  these	  complexes	  in	  human	  cancer.	  Furthermore,	  we	  discuss	  the	  role	  of	  repressive	  
complexes	   in	  modulating	   thresholds	   for	  gene	  activation	  and	   their	   importance	   for	   specification	  and	  
maintenance	  of	  cell	  fate.	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Introduction	  
The	   organization	   of	   DNA	   into	   chromatin	   is	   essential	   for	   the	   preservation	   of	   genomic	   integrity	   in	  
eukaryotic	  cells	  and	  is	  required	  for	  the	  correct	  transmission	  of	  genetic	  information	  over	  generations.	  
In	   addition	   to	   the	  physical	   role	  of	   compacting	   and	  protecting	  DNA,	   the	   chromatin	  conformation	   is	  
closely	   correlated	   with	   the	   expression	   state	   of	   the	   genes	   within	   its	   structure.	   Genes	   present	   in	   a	  
dense	  chromatin	  environment	  are	  less	  available	  to	  the	  transcriptional	  machinery	  and	  transcribed	  to	  a	  
lesser	   extent	   than	   genes	   found	   in	   looser,	   and	  more	   permissive,	   chromatin	   domains.	   Chromatin	   is	  
subject	  to	  highly	  dynamic	  modifications,	  playing	  important	  roles	  in	  regulating	  the	  availability	  of	  DNA	  
and	   thus	   gene	   expression.	   This	   regulation	   includes	   the	   exchange	   of	   histone	   variants,	   nucleosome	  
remodeling	   by	   ATP-­‐dependent	   remodeling	   complexes	   as	  well	   as	   posttranslational	  modifications	   of	  
DNA	  and	  histones	  (Kouzarides,	  2007).	  
	  
Protruding	  N-­‐terminal	  tails	  of	  the	  core	  histones	  (Luger	  et	  al.,	  1997),	  as	  well	  as	  the	  linker	  histone	  H1,	  
are	  subject	  to	  a	  vast	  array	  of	  posttranslational	  modifications,	  some	  of	  which	  are	  associated	  with	  the	  
transcriptional	  state	  of	  the	  underlying	  gene,	  while	  others	  appear	  to	  play	  roles	  in	  chromatin	  processes	  
such	   as	   cell	   cycle	   regulation	   or	   the	   DNA	   damage	   response.	   Histone	   modifications	   have	   different	  
biochemical	   functions:	  One,	   they	   serve	  as	  docking	   sites	   for	  proteins	  containing	  conserved	  domains	  
interacting	  with	   the	  modified	   residues,	   thus	   recruiting	  other	   factors	   to	   relevant	  genomic	   loci.	  Two,	  
charged	   modifications,	   such	   as	   lysine	   acetylation	   neutralizes	   the	   positive	   charge	   of	   the	   histones,	  
leading	   to	   decreased	   binding	   of	   the	   negatively	   charged	  DNA	   strand,	   thus	   loosening	   the	   chromatin	  
structure	  and	  promoting	  transcriptional	  activity	  (Kouzarides,	  2007).	  	  
	  
The	   various	   cells	   of	   an	   adult	   organism	   display	   distinct	   phenotypes,	   yet	   they	   all	   rely	   on	   the	   same	  
underlying	   genome.	   To	   establish	   cell	   identity,	   the	   correct	   set	   of	   genes	  must	   be	   transcribed,	  while	  
other	  genes	  must	  be	  kept	  in	  a	  silent	  state,	  and	  this	  pattern	  of	  gene	  expression	  must	  be	  maintained	  in	  
the	  differentiated	  cell	  and	  propagated	   through	  cell	  generations.	  Since	  chromatin	   regulators	  ensure	  
stable	   and	   heritable	   cell	   and	   tissue	   specific	   gene	   expression	   patterns	   over	   subsequent	   cell	  
generations,	  they	  are	  important	  for	  specifying	  and	  maintaining	  cell	  identity	  (Orkin	  and	  Hochedlinger,	  
2011).	  	  
	  
With	  chromatin	  modifiers	  being	  important	  for	  maintaining	  cell	  identity,	  it	  is	  not	  surprising	  that	  their	  
deregulation	   can	   have	   deleterious	   effects	   on	   cell	   fate	   and	   functions.	   Indeed,	   many	   chromatin	  
modifiers	  are	  essential	  for	  normal	  development	  and	  are	  often	  found	  deregulated	  in	  human	  disease,	  
including	  cancer.	  One	  intriguing	  prospect	  of	  this	  is	  that	  while	  genetic	  mutations	  are	  irreversible	  and	  
thus	   difficult	   to	   target	   clinically,	   chromatin	   modifications	   are	   reversible	   and	   might	   thus	   present	  
promising	   therapeutic	   targets.	   In	   fact,	   intense	   research	   efforts	   are	   currently	   going	   into	   developing	  
inhibitors	  specifically	   targeting	  chromatin-­‐associated	  proteins,	  some	  of	  which	  are	  already	   in	  clinical	  
trials	  and	  others	  in	  clinical	  use	  (Helin	  and	  Dhanak,	  2013).	  
	  
In	  this	  review,	  we	  discuss	  the	  role	  of	  chromatin-­‐mediated	  transcriptional	  repression	  with	  a	  particular	  
focus	  on	  Polycomb	  Repressive	  Complexes,	  PRC1	  and	  PRC2,	  and	  the	  Hdac1/2-­‐containing	  complexes,	  
Sin3,	  NuRD	  and	  CoREST.	  We	  describe	  their	  mechanisms	  of	  action	  in	  stem	  cells	  and	  development	  as	  
well	  as	  their	  deregulation	  in	  cancer	  and	  emerging	  strategies	  for	  targeting	  them	  therapeutically.	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Polycomb	  Repressive	  Complexes	  
The	   Polycomb	   group	   (PcG)	   proteins	   were	   originally	   identified	   in	   Drosophila,	   as	   transcriptional	  
repressors	  required	  for	  the	  correct	  spatiotemporal	  expression	  of	  developmental	  regulators	  along	  the	  
body	   axis	   and	  mutant	   flies	   develop	   abnormally	   with	   homeotic	   transformations.	   The	   PcG	   proteins	  
assemble	  into	  large	  multi-­‐protein	  complexes,	  the	  best-­‐characterized	  being	  PRC1	  and	  PRC2	  (Figure	  1).	  
PRC1	   homologs	   have	   been	   identified	   in	  metazoan	   species	   from	   flies	   to	  mammals,	  while	   the	   PRC2	  
homologs	  are	  also	  found	  in	  plants	  and	  nematodes	  (Margueron	  and	  Reinberg,	  2011).	  
	  
PRC1	  
Drosophila	   PRC1	   consists	   of	   Pc	   (Polycomb,	   a	   chromodomain-­‐containing	   protein	   with	   affinity	   for	  
H3K27me3),	  dRing	   (catalyzing	  H2A	  ubiquitylation),	  Psc	   (Posterior	   sex	  combs,	   involved	   in	   chromatin	  
compaction)	  and	  Ph	  (Polyhomeotic).	  Mammalian	  genomes	  encode	  several	  homologs	  of	  each	  of	  the	  
Drosophila	   PRC1	   components	   with	   five	   CBX	   homologs	   (CBX2/4/6/7/8),	   two	   ubiquitin	   ligases	  
(RING1A/B),	  six	  PCGF	  family	  members	  (PCGF1-­‐6,	  homologous	  to	  Psc)	  and	  three	  PHC	  family	  members	  
(Ph	   homologs).	   In	   mammalian	   cells,	   PRC1	   catalyzes	   H2AK119	   ubiquitylation	   (H2AK119ub1)	   and	  
promotes	  chromatin	  compaction	  (Di	  Croce	  and	  Helin,	  2013).	  
	  
PRC2	  
Mammalian	  PRC2	  contains	  the	  core	  components	  EZH2	  or	  its	  closely	  related	  homolog	  EZH1	  (homologs	  
of	  Drosophila	   E(z)),	   EED	   (homolog	   of	   Esc)	   and	   SUZ12	   (homolog	   of	   Su(z)12),	   all	   three	   of	  which	   are	  
required	  for	  catalytic	  activity	   in	  vitro,	  while	  association	  with	  the	  histone	  chaperone	  RBBP4/7	  seems	  
to	   be	   required	   for	   catalytic	   activity	   in	   vivo.	   The	   EZH	   component	   contains	   a	   SET	   domain,	   which	  
catalyzes	  the	  methylation	  of	  lysine	  27	  of	  histone	  H3	  (Margueron	  and	  Reinberg,	  2011).	  
	  
Transcriptional	  Repression	  by	  PRCs	  
Whereas	  H3K27	   is	   the	  essential	  physiological	  substrate	  for	  PRC2	  (Pengelly	  et	  al.,	  2013),	   the	  precise	  
functional	   importance	   of	   PRC-­‐mediated	   histone	   marks	   remains	   unclear.	   The	   functional	   role	   of	  
H3K27me3	   has	   primarily	   been	   studied	   as	   a	   recruitment	   mechanism	   for	   CBX-­‐containing	   PRC1	  
complexes,	   and,	   in	  Drosophila,	   the	   catalytic	   activity	   of	   E(z)	   is	   required	   for	   target	   gene	   repression	  
(Muller	   et	   al.,	   2002),	   while	   H2AK119ub1	   is	   believed	   to	   promote	   chromatin	   compaction	   and	  
transcriptional	   repression.	   In	   vitro	   data	   shows	   that	   PRCs	   promote	   condensation	   of	   nucleosomal	  
arrays	   (Francis	   et	   al.,	   2004)	   and	   PRC-­‐binding	   in	   Drosophila	   mediates	   chromatin	   compaction	   and	  
organization	  into	  functional	  domains,	  called	  PcG	  bodies,	  as	  well	  as	  long-­‐range	  interactions	  important	  
for	  higher-­‐order	  chromatin	  organization	  (Bantignies	  et	  al.,	  2011;	  Sexton	  et	  al.,	  2012).	  Recently,	  the	  E3	  
ligase	  activity	  of	  the	  Ring1	  component	  of	  PRC1	  was	  shown	  to	  be	  dispensable	  for	  recruitment	  to	  and	  
compaction	  of	  chromatin	  at	  the	  Hox	  loci	  in	  mESCs	  (Endoh	  et	  al.,	  2012).	  However,	  the	  catalytic	  activity	  
was	   indispensable	   for	   target	   gene	   repression,	   indicating	   that	   H2A	   ubiquitylation	   and	   chromatin	  
condensation	  represent	  two	  separate	  mechanisms	  of	  PRC1-­‐mediated	  repression	  (Endoh	  et	  al.,	  2012).	  
Alternative	   roles	   of	   H2AK119ub1	   in	   PRC-­‐mediated	   repression	   include	   prevention	   of	   H3K4me3	  
deposition,	  inhibition	  of	  RNA	  polymerase	  II	  activity	  and	  prevention	  of	  H2A-­‐H2B	  dimer	  eviction	  from	  
transcribed	  regions	  (Di	  Croce	  and	  Helin,	  2013).	  	  
	  
Recruitment	  of	  Polycomb	  Repressive	  Complexes	  
In	  Drosophila,	   PcG	   proteins	   are	   recruited	   to	   DNA	   stretches	   termed	   Polycomb	   Response	   Elements	  
(PREs).	   A	   distinct	   PRE	   for	   mammalian	   cells	   remains	   elusive,	   but	   mammalian	   PRCs	   bind	   CpG	   rich	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promoters	   of	   their	   target	   genes	   (Ku	   et	   al.,	   2008),	   and	   CpG	   rich	   sequences	   have	   been	   shown	   to	  
mediate	  PRC2	  recruitment	  (Mendenhall	  et	  al.,	  2010).	  Several	  different	  recruitment	  mechanisms	  for	  
PRC2	  have	  been	  suggested,	  including	  association	  with	  near-­‐stoichiometric	  interaction	  partners	  (such	  
as	  PCL1-­‐3,	  AEBP2,	  JARID2),	  association	  with	  transcription	  factors	  and	  recruitment	  by	  ncRNA	  (Di	  Croce	  
and	  Helin,	  2013).	  The	  WD40	  domains	  of	  the	  RBBP4/7	  subunit	  confer	  general	  histone-­‐binding	  activity	  
to	   PRC2,	   while	   those	   of	   EED	   specifically	   interact	   with	   H3K27me3,	   thus	   providing	   a	   potential	  
mechanism	   for	   spreading	   and	   propagation	   of	   the	  mark.	   In	   addition,	   JARID2	   and	   AEBP2	   have	   both	  
been	  shown	  to	  confer	  weak	  CpG-­‐rich	  DNA-­‐binding	  activity	  to	  the	  complex,	  while	  the	  Tudor	  domains	  
of	  PCL1-­‐3	  were	  recently	  shown	  to	  bind	  H3K36me2/3	  (Di	  Croce	  and	  Helin,	  2013).	  The	  involvement	  of	  
ncRNAs	   in	   PRC	   recruitment	   has	   been	   most	   extensively	   studied	   in	   the	   context	   of	   X	   chromosome	  
inactivation.	   The	   accumulation	  of	  H3K27me3	  on	   the	   inactive	   X	   chromosome	   is	   dependent	   on	   XIST	  
expression,	   and	   the	  A	   repeats	  of	  XIST	  has	  been	   shown	   to	  bind	  PRC2	   (Zhao	  et	   al.,	   2008).	  However,	  
XIST	  lacking	  the	  A	  repeats	  is	  capable	  of	  recruiting	  PRC2,	  indicating	  the	  involvement	  of	  other	  domains	  
of	  XIST	  in	  PRC2	  recruitment	  (Kohlmaier	  et	  al.,	  2004).	  While	  a	  number	  of	  studies	  show	  association	  of	  
ncRNAs	  with	  PRC2	  members,	  the	  reports	  differ	  in	  the	  types	  of	  RNAs	  identified,	  specific	  binding	  areas	  
of	  the	  RNAs	  as	  well	  as	  the	  PRC2	  component	  involved	  in	  the	  interaction,	  and	  the	  exact	  role	  of	  ncRNAs	  
in	  PRC2	  recruitment	   remains	  unclear	   (da	  Rocha	  et	  al.,	  2014;	  Davidovich	  et	  al.,	  2013;	  Kaneko	  et	  al.,	  
2014;	  Zhao	  et	  al.,	  2010).	  	  
	  
Several	   lines	   of	   evidence	   obtained	   in	   Drosophila	   and	   mammalian	   cells	   have	   shown	   that	   PRC1	  
recruitment	  to	  target	  sites	   is	  dependent	  on	  PRC2	  and	  H3K27me3.	  However,	  recent	  studies	   in	  PRC2	  
knockout	  mESCs	  have	   shown	  only	   a	  minor	  decrease	   in	  H2AK119ub1	   levels	  despite	   a	   global	   loss	  of	  
H3K27me3	   (Leeb	   et	   al.,	   2010).	   An	   explanation	   for	   this	   observation	   has	   been	   provided	   by	   the	  
characterization	   of	   PRC2-­‐independent	   RING1-­‐containing	   complexes	   without	   any	   CBX	   component,	  
which	  rely	  on	  their	  complex	  partners	  RYBP/YAF2	  and	  L3MBTL2	  as	  well	  as	  the	  association	  with	  DNA	  
binding	  proteins	  such	  as	  KDM2B	  for	  their	  recruitment	  to	  CpG	  rich	  promoters	  (Farcas	  et	  al.,	  2012;	  Gao	  
et	  al.,	  2012;	  Qin	  et	  al.,	  2012;	  Tavares	  et	  al.,	  2012;	  Wu	  et	  al.,	  2013).	  Similar	  to	  what	  has	  been	  shown	  in	  
Drosophila	   (Lagarou	  et	  al.,	  2008),	   the	  mammalian	  KDM2B-­‐RING1B	  complex	  appears	   to	  have	  higher	  
catalytic	  activity	  towards	  H2AK119ub1	  than	  PRC1.	  
	  
Accompanying	   the	  changes	   in	   transcriptional	  programs	  during	  differentiation,	  PRC	  binding	  changes	  
dynamically	  (Bracken	  et	  al.,	  2006;	  Mohn	  et	  al.,	  2008).	  Whether	  the	  patterns	  of	  PRC	  binding	  in	  various	  
cell	   types	   depend	   on	   differential	   expression	   of	   interaction	   partners	   or	   ncRNAs,	   or	   if	   PRC	   binding	  
differs	   simply	   as	   a	   consequence	   of	   differential	   gene	   expression	   patterns	   and	   recruitment	   to	  
untranscribed	   genes	   is	   still	   unclear.	   Elucidating	   the	   mechanisms	   regulating	   PRC	   binding	   to	   target	  
genes	  is	  essential	  for	  our	  understanding	  of	  the	  nature	  of	  PRC-­‐mediated	  transcriptional	  repression.	  
	  
HDAC1/2-­‐Containing	  Complexes	  
HDAC1	   and	   HDAC2	   are	   highly	   homologous	   class	   I	   histone	   deacetylases	   found	   in	   large	   multimeric	  
complexes,	  the	  most	  extensively	  studied	  being	  Sin3,	  NuRD	  and	  CoREST	  (Figure	  2),	  which	  are	  found	  in	  
species	  from	  yeast	  to	  human.	  In	  addition	  to	  the	  HDAC1/2	  catalytic	  core	  and	  RBBP4/7	  that	  are	  shared	  
among	   the	   complexes,	   they	   incorporate	   different	   subunits,	   thus	   providing	   target	   specificity	   or	  
additional	  catalytic	  activities.	  Importantly,	  many	  of	  the	  subunits	  have	  several	  homologs,	  allowing	  for	  
combinatorial	  assembly	  of	  specific	  complexes	  with	  context	  dependent	   functions	   (Kelly	  and	  Cowley,	  
2013).	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SIN3	  
Mammalian	   genomes	   encode	   two	   homologs	   of	   SIN3	   (SIN3A/B),	   which	   associate	   individually	   with	  
HDAC1/2,	  RBBP4/7,	  SDS3	  and	  the	  SIN3-­‐associated	  proteins	  SAP18	  and	  SAP30	  to	  form	  the	  core	  SIN3	  
complex.	  Different	  studies	  have	  identified	  additional	   interaction	  partners	   including	  MeCP2	  (methyl-­‐
CpG-­‐binding	   protein),	   RBP1	   (RB-­‐binding	   protein),	   BRMS1	   (breast	   cancer	   metastasis	   suppressor),	  
ING1/2	   (inhibitor	   of	   growth),	   SAP25,	   SAP130	   and	   SAP180	   as	   well	   as	   the	   histone	   demethylase	  
RBP2/KDM5A	  (Hayakawa	  and	  Nakayama,	  2011;	  Kadamb	  et	  al.,	  2013).	  
	  
NuRD	  
The	   NuRD	   (Nucleosome	   Remodeling	   Deacetylase)	   complex	   couples	   two	   important	   chromatin-­‐
modifying	   activities,	   namely	   nucleosome	   remodeling	   through	   the	   ATP-­‐dependent	   CHD3/4	   helicase	  
subunit	   and	   histone	   deacetylation	   catalyzed	   by	   HDAC1/2.	   Additional	   components	   include	   the	  
scaffolding	   proteins	   GATAD2A/B,	   conferring	   histone-­‐binding	   properties	   to	   the	   complex,	   while	   the	  
MBD2/3	   and	   MTA1/2/3	   subunits	   mediate	   binding	   to	   DNA	   and	   transcription	   factors,	   respectively	  
(Hayakawa	   and	   Nakayama,	   2011;	   Lai	   and	   Wade,	   2011).	   Some	   results	   have	   suggested	   that	   NuRD	  
interacts	  with	  the	  histone	  demethylase	  LSD1/KDM1A,	  potentially	  adding	  yet	  another	  catalytic	  activity	  
to	  its	  repertoire	  (Wang	  et	  al.,	  2009b).	  However,	  this	  association	  is	  not	  observed	  in	  other	  purifications,	  
possibly	  reflecting	  context	  specific	  interactions.	  
	  
CoREST	  
Originally	   described	   as	   co-­‐repressor	   of	   REST	   (RE1-­‐silencing	   transcription	   factor),	   CoREST	   was	  
subsequently	   found	   in	   complex	   with	   HDAC1/2	   and	   RBBP4/7	   (although	   not	   retrieved	   in	   some	  
purifications)	   with	   additional	   subunits	   including	   Sox-­‐like	   protein,	   ZNF217,	   BHC80	   and	   the	   histone	  
demethylase	  LSD1	  (Hayakawa	  and	  Nakayama,	  2011).	  LSD1	  has	  catalytic	  activity	  towards	  H3K9me1/2	  
and	  H3K4me1/2	   (Metzger	   et	   al.,	   2005;	   Shi	   et	   al.,	   2004).	   However,	   in	   the	   context	   of	   CoREST,	   LSD1	  
seems	   to	   preferentially	   target	   H3K4me1/2,	   while	   primarily	   exerting	   its	   function	   as	   a	   H3K9	  
demethylase	  when	  associated	  with	  nuclear	  receptors	  (Kooistra	  and	  Helin,	  2012).	  
	  
Transcriptional	  regulation	  by	  HDAC1/2-­‐Containing	  Complexes	  
SIN3,	  NuRD	  and	  CoREST	   are	   all	   large,	  multimeric	   complexes	   that	   serve	   as	   scaffolds	   for	   assembling	  
different	  catalytic	  activities	  at	  relevant	  genomic	  loci.	  For	  NuRD,	  the	  CHD3/4	  helicase	  activity	  has	  been	  
shown	   to	   promote	   deacetylase	   activity,	   possibly	   by	   promoting	   the	   accessibility	   of	   the	   nucleosome	  
substrate	   through	   ATP-­‐dependent	   nucleosome	   sliding	   (Xue	   et	   al.,	   1998).	   It	   is	   note-­‐worthy	   that	   all	  
three	  complexes	  combine	  their	  core	  deacetylase	  activity	  with	  demethylase	  interaction	  partners.	  For	  
CoREST,	   the	   two	   catalytic	   activities	   appear	   to	   be	   interdependent	   with	   deacetylation	   promoting	  
demethylation	   (Lee	   et	   al.,	   2006a),	   pointing	   to	   a	   functional	   interplay	   extending	   beyond	   mere	   co-­‐
localization.	  
	  
In	   accordance	   with	   histone	   acetylation	   being	   associated	   with	   transcriptional	   activation,	   HDAC-­‐
containing	   complexes	   reversing	   this	   modification	   are	   traditionally	   described	   as	   co-­‐repressors	  
promoting	  transcriptional	  repression	  of	  their	  target	  genes.	  Importantly,	  however,	  it	  has	  been	  shown	  
that	  dynamic	  acetylation/deacetylation	  is	  required	  for	  active	  transcription	  to	  occur,	  thus	  pointing	  to	  
important	  roles	  of	  HDAC-­‐containing	  complexes	  in	  activating	  transcription	  in	  addition	  to	  their	  function	  
as	  co-­‐repressors	  (Clayton	  et	  al.,	  2006;	  Kelly	  and	  Cowley,	  2013).	  Indeed,	  ChIP-­‐sequencing	  studies	  show	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that	  HDACs	  also	  co-­‐localize	  with	  acetyltransferases	  at	  transcriptionally	  active	  loci,	  presumably	  acting	  
to	   reset	   acetylation	   levels	   after	   gene	   activation	   (Wang	   et	   al.,	   2009c).	   Thus,	   the	   transcriptional	  
regulation	  exerted	  by	  HDAC1/2-­‐containing	  complexes	  might	  be	  highly	  context	  dependent.	  	  	  
	  
Recruitment	  of	  HDAC1/2-­‐Containing	  Complexes	  
Recruitment	  of	   the	  HDAC1/2-­‐containing	  complexes	  seems	  to	  rely	  on	  cell-­‐type	  specific	   transcription	  
factor	   binding	   as	   well	   as	   chromatin-­‐binding	   domains	   within	   certain	   subunits	   (Hayakawa	   and	  
Nakayama,	   2011).	   Each	   of	   the	   complexes	   contain	   at	   least	   two	   subunits	   with	   histone-­‐binding	  
properties	  such	  as	  PHD-­‐fingers,	  chromodomains	  and	  Tudor	  domains	  as	  well	  as	  the	  WD40	  repeats	  of	  
RBBP4/7	  (Kelly	  and	  Cowley,	  2013).	  
	  
The	   existence	   of	   several	   homologs	   for	   most	   of	   the	   components	   indicates	   that	   specific	   complex	  
composition	  might	  confer	  distinct	  binding	  patterns	  and	  influence	  their	  biological	  function	  in	  different	  
cell	   types	   (Kelly	   and	   Cowley,	   2013).	   For	   instance,	   NuRD	   complex	   containing	  MBD2	   is	   functionally	  
distinct	   from	  MBD3-­‐NuRD	   (Le	   Guezennec	   et	   al.,	   2006).	  MBD2	   recruits	   NuRD	   to	  methylated	   CpGs,	  
while	  MBD3	  is	  unable	  to	  bind	  methyl-­‐cytosine	  due	  to	  amino	  acid	  substitutions	  in	  the	  methyl-­‐binding	  
domain.	  However,	  NuRD	  is	  recruited	  to	  some	  target	  genes	  independently	  of	  their	  methylation	  status,	  
and	  the	  MBD	  component	  is	  thus	  only	  partly	  responsible	  for	  NuRD	  recruitment	  (Baubec	  et	  al.,	  2013).	  
Similarly,	   the	   MTA	   proteins	   are	   incorporated	   into	   distinct	   NuRD	   complexes	   with	   differential	  
transcription	  factor	  binding	  and	  recruitment	  to	  specific	  genomic	  loci	  (Lai	  and	  Wade,	  2011).	  
	  
Thus,	  for	  PRCs	  as	  well	  as	  HDAC1/2-­‐containing	  complexes,	  it	  seems	  that	  specific	  subunit	  composition	  
and	   association	   with	   cell-­‐type	   specific	   interaction	   partners	   is	   important	   for	   regulating	   their	  
recruitment	  and	  biological	  function.	  
	  
Chromatin	  Repressive	  Complexes	  in	  Pluripotent	  Stem	  Cells	  
ESCs	  display	  an	  open	  and	  permissive	  chromatin	  structure	  with	  low	  levels	  of	  DNA	  methylation	  and	  a	  
greater	  abundance	  of	  activating	  histone	  modifications,	  such	  as	  H3K4me3	  and	  histone	  acetylation.	  In	  
addition,	  structural	  proteins	  such	  as	  heterochromatin	  protein	  1	  (HP1),	  the	  linker	  histone	  H1	  and	  the	  
core	   histones	   display	   highly	   dynamic	   kinetics	   in	   their	   association	   with	   chromatin	   in	   ESCs,	   further	  
opening	   the	   chromatin	   structure	   (Azuara	   et	   al.,	   2006;	   Meshorer	   et	   al.,	   2006).	   The	   hyperdynamic	  
nature	   of	   ESC	   chromatin	   correlates	   with	   a	   very	   high	   level	   of	   transcriptional	   activity	   and	   a	   high	  
abundance	  of	  general	   transcription	   factors	  and	  chromatin	  modifiers	   (Efroni	  et	  al.,	  2008),	  central	   to	  
maintaining	   transcriptional	   patterns	   in	   the	   open	   chromatin	   structure.	   Upon	   differentiation,	   the	  
overall	   chromatin	   structure	   shifts	   towards	   a	   tighter,	  more	   restrictive	   configuration	  with	   decreased	  
transcriptional	   activity	   and	   concomitant	   accumulation	   of	   H3K27me3	   (Zhu	   et	   al.,	   2013)	   as	   well	   as	  
induction	  of	  large	  H3K9me3-­‐positive	  heterochromatic	  foci	  (Meshorer	  et	  al.,	  2006).	  	  
	  
Chromatin	  regulators	  along	  with	  tightly	  regulated	  transcription	  factor	  circuits	  play	  important	  roles	  in	  
balancing	  self-­‐renewal	  and	  pluripotency	  in	  ESCs,	  and	  the	  open	  chromatin	  environment	  appears	  to	  be	  
important	   for	   the	   maintenance	   of	   pluripotency.	   Conversely,	   the	   open,	   permissive	   chromatin	  
environment	  necessitates	  the	  action	  of	  chromatin	  repressive	  complexes	   in	  order	  to	  protect	  against	  
inappropriate	   transcription	   of	   differentiation	   factors	   as	   well	   as	   for	   the	   orchestration	   of	  
differentiation	   through	   the	   timely	   repression	   of	   pluripotency-­‐associated	   genes	   (Orkin	   and	  
Hochedlinger,	  2011).	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Polycomb	  Repressive	  Complexes	  in	  Embryonic	  Stem	  Cells	  
PRCs	   are	   highly	   expressed	   in	   ESCs	   and	  have	   been	   shown	   to	   bind	  CpG-­‐rich	   promoters	   of	   genes	   for	  
transcription	  factors	  and	  signaling	  molecules	  controlling	  development	  (Boyer	  et	  al.,	  2006;	  Bracken	  et	  
al.,	  2006;	  Lee	  et	  al.,	  2006b).	   In	  addition,	  PcG	  proteins	  and	  their	  marks	  are	  found	  at	  some	  repetitive	  
elements	  and	  involved	  in	  imprinting	  and	  X-­‐chromosome	  inactivation	  (Casa	  and	  Gabellini,	  2012).	  
	  
While	  the	  PRC2	  components	  are	  essential	  for	  mouse	  development,	  mESCs	  lacking	  Eed,	  Suz12	  or	  Ezh2	  
can	  be	  derived	   from	  knockout	  embryos,	   yielding	   similar	  phenotypes	  with	   retention	  of	   self-­‐renewal	  
capacity,	  loss	  of	  H3K27me2/3	  and	  in	  vitro	  differentiation	  defects.	  Consistent	  with	  the	  in	  vitro	  defects,	  
chimeric	   embryo	   complementation	   studies	   show	   that	   knockout	  mESCs	   initiate	   differentiation,	   but	  
display	   abnormal	   long-­‐term	   repression	   of	   pluripotency	   factors	   and	   lack	   robust	   induction	   of	  
differentiation	  factors	  (Chamberlain	  et	  al.,	  2008;	  Montgomery	  et	  al.,	  2005;	  Pasini	  et	  al.,	  2007;	  Shen	  et	  
al.,	  2008).	  Notably,	  the	  passage	  number	  of	  Eed-­‐/-­‐	  cells	  influences	  the	  phenotype:	  high-­‐passage	  Eed-­‐/-­‐	  
cells	  display	  more	  pronounced	  derepression	  of	  target	  genes	  and	  a	  global	   loss	  H3K27me1,	  while	  the	  
phenotype	   of	   low-­‐passage	   Eed-­‐/-­‐	   cells	   appears	   identical	   to	   those	   of	   Ezh2-­‐/-­‐	   and	   Suz12-­‐/-­‐	   cells	  
(Chamberlain	  et	  al.,	  2008).	  
	  
Ring1b-­‐deficient	  mESCs	   have	   reduced	   levels	   of	   H2AK119ub1,	   a	   slight	   deregulation	   of	   some	   target	  
genes	   and	   a	   loss	   of	   differentiation	   potential	   (Leeb	   and	  Wutz,	   2007),	   while	   Ring1a/Ring1b	   double	  
knockout	  mESCs	   lose	   the	   ability	   to	   self-­‐renew	   after	   a	   few	  passages	   and	   show	  defects	   in	   cell	   cycle	  
regulation,	   pointing	   to	   PRC2-­‐independent	   roles	   of	   Ring1a/Ring1b	   (Endoh	   et	   al.,	   2008).	   Knockdown	  
studies	   show	   that	   the	   non-­‐canonical	   PRC1	   components	   Rybp	   or	   Kdm2/Fbxl10	   are	   dispensable	   for	  
self-­‐renewal,	  while	  loss	  of	  either	  factor	  diminishes	  H2AK119ub1	  levels	  and	  compromises	  the	  in	  vitro	  
differentiation	  potential	  (Gao	  et	  al.,	  2012;	  Wu	  et	  al.,	  2013).	  Recently,	  different	  Cbx	  subunits	  of	  PRC1	  
were	  shown	  to	  have	  specific	  roles	  with	  Cbx7	  being	  required	  for	  maintaining	  the	  pluripotent	  state	  of	  
mESCs,	  with	  a	   shift	   in	   composition	   to	  Cbx2/4	  being	   important	  during	  differentiation	   (Morey	  et	   al.,	  
2012).	  
	  
HDAC1/2-­‐Containing	  Complexes	  in	  Embryonic	  Stem	  Cells	  
Hdac1	  and	  Hdac2	  are	  both	  dispensable	  for	  mESC	  self-­‐renewal,	  but	  while	  Hdac2-­‐/-­‐	  cells	  retain	  their	  in	  
vitro	  differentiation	  potential,	  Hdac1	   knockout	  disrupts	  normal	  differentiation	   (Dovey	  et	  al.,	  2010).	  
Several	  NuRD	  subunits	  have	  been	  shown	   to	   interact	  with	  core	  pluripotency	   factors,	   including	  Oct4	  
and	   Nanog,	   forming	   the	   NODE	   complex	   (Nanog-­‐	   and	   Oct4-­‐associated	   deacetylase)	   (Liang	   et	   al.,	  
2008),	   which	   might	   be	   functionally	   distinct	   from	   Mbd3-­‐containing	   NuRD.	   While	   the	   relative	  
contributions	   of	   different	   Hdac1/2-­‐containing	   complexes	   remain	   unclear,	   several	   studies	   show	  
important	  roles	  of	  subunits	  of	  each	  of	  these	  complexes	  in	  mESCs.	  
	  
In	  vitro	  culture	  of	  Sin3a-­‐/-­‐	  blastocysts	  yield	  smaller	  colonies	  and	   insufficient	  outgrowth	  of	   the	   ICM,	  
showing	  important	  roles	  of	  Sin3a	  in	  the	  establishment	  of	  mESCs	  (Cowley	  et	  al.,	  2005),	  and	  consistent	  
with	  the	  peri-­‐implantation	  lethality	  observed	  for	  Sin3a-­‐/-­‐	  mice.	  Mbd3-­‐deficient	  mESCs	  can	  be	  derived	  
and	   propagated	   in	   culture,	   but	   display	   defects	   during	   differentiation	   (Kaji	   et	   al.,	   2006;	   Rais	   et	   al.,	  
2013).	   Knocking	   out	   Lsd1	   in	  mESCs	   leads	   to	   reduced	   CoREST	   levels,	   a	   slight	   deregulation	   of	   gene	  
expression	  and	  defects	  during	  embryoid	  body	  formation	  with	   incomplete	  silencing	  of	  pluripotency-­‐
associated	  genes	   (Foster	  et	  al.,	  2010;	  Wang	  et	  al.,	  2009a).	  Lsd1	  has	  also	  been	  shown	  to	  co-­‐localize	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with	   NuRD	   at	   the	   enhancers	   of	   pluripotency-­‐associated	   genes,	   where	   it	   is	   required	   for	   the	  
downregulation	  of	  H3K4me1-­‐levels	  during	  differentiation	  (Whyte	  et	  al.,	  2012).	  	  
	  
Chromatin	  Repressive	  Complexes	  and	  Pluripotency	  
Many	  repressive	  complexes	  do	  not	  seem	  to	  be	  essential	   for	  the	  self-­‐renewal	  of	  ESCs,	  while	  both	   in	  
vivo	  and	   in	   vitro	  data	   demonstrate	   their	   requirement	   for	   pluripotency.	   It	   has	   been	   suggested	   that	  
one	  of	  the	  key	  functions	  of	  chromatin	  regulation	  is	  in	  noise	  reduction,	  meaning	  that	  the	  presence	  of	  
nucleosomes	   and	   other	   chromatin-­‐bound	   factors	   act	   to	   limit	   the	   propensity	   of	   promiscuous	  
transcriptional	  activity	  such	  that	  several	  cues	  need	  to	  act	  in	  concert	  in	  order	  for	  transcription	  to	  take	  
place.	   Studies	   from	   yeast	   support	   this	   theory:	   By	   competing	   with	   transcription	   factors	   and	   the	  
transcriptional	  machinery	  for	  access	  to	  promoters,	  chromatin	  acts	  to	  increase	  the	  threshold	  for	  gene	  
activation	  and	   limit	   transcriptional	  noise	   (Lam	  et	  al.,	  2008),	  see	  also	  e.g.	   (Chi	  and	  Bernstein,	  2009).	  
This	  view	  might	  help	  explain	  the	  phenotype	  of	  ESCs	  lacking	  chromatin	  repressive	  complexes:	  As	  long	  
as	  cells	  are	  grown	  in	  defined	  media,	  loss	  of	  a	  complex	  does	  not	  lead	  to	  widespread	  gene	  activation	  or	  
changes	   in	   cell	   identity.	   However,	   it	   might	   lower	   the	   threshold	   for	   gene	   activation	   giving	   rise	   to	  
transcriptional	   noise.	   Thus,	   during	   differentiation	   in	   an	   environment	   with	   multiple	   signals	   and	  
different	  types	  of	  cells,	  the	  more	  relaxed	  chromatin	  makes	  cells	   lacking	  repressive	  complexes	  more	  
susceptible	   to	   aberrant	   activation	   of	   gene	   expression,	   which	   can	   result	   in	   differentiation	   and	  
developmental	   failures.	   The	   normal	   role	   of	   the	   repressive	   chromatin	   complexes	   is	   therefore	   to	  
ensure	  that	  sustained	  and	  strong	  signals	  are	  required	  for	  changing	  the	  transcription	  program	  and	  the	  
specification	  of	  differentiation.	  The	  importance	  of	  defined	  media	  in	  this	  context	  is	  illustrated	  by	  the	  
early	  observations	  that	  knockout	  of	  e.g.	  Ezh2	  or	  Mbd3	  was	   incompatible	  with	  the	  establishment	  of	  
pluripotency	  (Kaji	  et	  al.,	  2007;	  O'Carroll	  et	  al.,	  2001).	  Both	  observations	  have	  since	  been	  refuted	  by	  
the	   establishment	   of	   knockout	  mESCs	   lacking	   either	   factor,	  most	   likely	   through	   the	   refinement	   of	  
experimental	  procedures	  or	   the	   introduction	  of	  optimized	  culture	  conditions	  such	  as	  2i/LIF	   (Rais	  et	  
al.,	  2013;	  Shen	  et	  al.,	  2008).	  
	  
In	  the	  context	  of	  pluripotent	  cells,	  a	  much-­‐debated	  feature	  is	  the	  observation	  of	  bivalent	  domains	  in	  
the	  promoters	  of	  developmental	  genes,	  defined	  by	  the	  presence	  of	  H3K4me3	  alongside	  H3K27me3	  
(Azuara	   et	   al.,	   2006;	   Bernstein	   et	   al.,	   2006).	   This	   co-­‐occurrence	   observed	   by	   ChIP-­‐sequencing	  
approaches	   might	   represent	   the	   two	   marks	   existing	   simultaneously	   on	   the	   same	   histone	   tail,	   on	  
opposite	  H3	  tails	  of	   the	  same	  nucleosome	  or	  on	  neighboring	  nucleosomes.	   In	  addition,	   it	  has	  been	  
argued	  that	  bivalent	  promoters	  might	  simply	  represent	  an	  artifact	  of	  heterogeneous	  cell	  populations.	  
While	  additional	  observations	  of	  bivalent	  domains	  in	  the	  early	  embryo	  and	  differentiated	  cell	  types	  
and	  the	  application	  of	  sequential	  ChIP	  and	  mass	  spectrometry	  approaches	  have	  shown	  the	  existence	  
of	  truly	  bivalent	  promoters,	  their	  functional	  relevance	  remains	  unclear.	  With	  all	  CpG	  rich	  promoters	  
being	   H3K4me3-­‐positive	   in	   mESCs	   (Mikkelsen	   et	   al.,	   2007)	   and	   PRC2	   being	   recruited	   to	   CpG-­‐rich	  
stretches,	  the	  co-­‐occurrence	  of	  H3K4me3	  and	  H3K27me3	  is	  to	  be	  expected.	  Bivalent	  genes	  are	  found	  
to	   be	   transcriptionally	   inactive,	   but	   are	   generally	   thought	   to	   be	   poised	   for	   activation	   upon	  
differentiation,	   thus	   providing	   plasticity	   to	   the	   chromatin	   structure	   (Voigt	   et	   al.,	   2013).	   However,	  
recent	  studies	  show	  that	  loss	  of	  H3K4me3	  from	  bivalent	  promoters	  does	  not	  disrupt	  the	  large-­‐scale	  
responsiveness	  of	  gene	  activation	  upon	  all	  trans-­‐retinoic	  acid-­‐induced	  differentiation	  of	  mESCs,	  thus	  
questioning	  the	  prevailing	  view	  of	  the	  functional	  relevance	  of	  bivalency	  (Denissov	  et	  al.,	  2014;	  Hu	  et	  
al.,	  2013).	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ChIP	   analyses	   show	   binding	   of	   the	   Chd4	   component	   of	   NuRD	   at	   bivalent	   Polycomb	   target	   gene	  
promoters	   and	   reveal	   potential	   co-­‐regulation	   of	   the	   two	   complexes	   with	   common	   target	   genes	  
gaining	   H3K27ac	   and	   losing	   PRC2	   binding	   as	   well	   as	   H3K27me3	   in	  Mbd3-­‐/-­‐	   cells	   (Reynolds	   et	   al.,	  
2012b).	  This	  indicates	  that	  NuRD	  and	  PRC2	  might	  be	  functionally	  linked	  through	  occupation	  of	  some	  
of	   the	  same	  genomic	   loci,	  where	  NuRD	  might	   facilitate	  PRC2	  recruitment	  and	  methylation	   through	  
deacetylation	   of	   H3K27.	   This	   potential	   co-­‐regulation	   is	   reminiscent	   of	   observations	   in	  Drosophila,	  
where	   HDAC1/RPD3	   collaborates	  with	   PcGs	   in	   repressing	   a	   subset	   of	   PcG	   target	   genes	   (Tie	   et	   al.,	  
2001).	  	  
	  
Interestingly,	  Hdac1	  and	  Mbd3	  have	  been	   found	   to	  associate	  with	   the	  promoters	  of	  many	  actively	  
transcribed	  genes,	  including	  core	  pluripotency	  factors.	  Importantly,	  however,	  comparative	  analysis	  of	  
mESCs	   showed	   that	   target	   gene	   expression	   was	   primarily	   upregulated	   upon	   Hdac1	   knockout,	  
indicating	   that	  NuRD	   acts	   as	   a	   transcriptional	   repressor	   even	   at	   actively	   transcribed	   genes	   (Kidder	  
and	   Palmer,	   2012).	   In	   a	   recent	   study,	   Reynolds	   et	   al.	   investigated	   the	   role	   of	   NuRD	   in	   regulating	  
pluripotency	   and	   lineage	   commitment	   of	   mESCs.	   The	   authors	   found	   that	   rather	   than	   silencing	  
pluripotency-­‐associated	   genes,	   NuRD	   is	   required	   to	   restrict	   transcript	   levels	   below	   a	   threshold,	  
thereby	   sensitizing	   cells	   to	  differentiation	   cues	   and	   facilitating	   lineage	   commitment	   in	   response	   to	  
the	  relevant	  stimuli	  (Reynolds	  et	  al.,	  2012a).	  Thus,	  NuRD	  and	  other	  repressive	  complexes	  might	  not	  
function	  as	  traditional	  silencers,	  but	  rather	  by	  fine-­‐tuning	  expression	  levels	  of	  their	  target	  genes	  (Hu	  
and	  Wade,	  2012;	  Reynolds	  et	  al.,	  2013).	  	  
	  
In	   the	   acquisition	   of	   pluripotency	   through	   reprogramming	   of	   somatic	   cells,	   the	   chromatin	  
environment	   undergoes	   major	   reorganization	   towards	   an	   open	   chromatin	   structure	   along	   with	  
erasure	   of	   DNA	   methylation	   and	   redistribution	   of	   histone	   modifications,	   and	   many	   chromatin	  
modifiers	   appear	   to	   influence	   this	   process.	   Cell	   fusion	   experiments	   using	  mESCs	  with	   knockout	   of	  
PRC1	  or	  PRC2	  components	  show	  that	   functional	  PRCs	  are	  required	   for	   reprogramming	  of	  human	  B	  
cells	   (Pereira	   et	   al.,	   2010).	   Similarly,	   shRNA-­‐mediated	   knockdown	   of	   PRC1	   or	   PRC2	   components	  
impaired	  the	  conversion	  of	  human	  fibroblasts	  to	  induced	  pluripotent	  stem	  cells	  (iPSCs)	  (Onder	  et	  al.,	  
2012),	  while	  ectopic	  Ezh2	  or	  Bmi1	  expression	  increases	  the	  efficiency	  of	  iPSC	  generation	  (Buganim	  et	  
al.,	  2012;	  Moon	  et	  al.,	  2011).	  In	  this	  context,	  it	  is	  important	  to	  keep	  in	  mind	  the	  differences	  between	  
mouse	   and	   human	   pluripotent	   cells.	   Indeed,	   Ezh2	   knockout	   does	   not	   impair	   iPSC	   formation	   from	  
MEFs	   (Fragola	  et	  al.,	  2013),	   indicating	   that	  Ezh2	   is	  not	   required	   for	   reprogramming	  of	  mouse	  cells.	  
However,	  the	  authors	  note	  that	  despite	  a	  global	  loss	  of	  H3K27me3	  upon	  Ezh2	  knockout,	  this	  mark	  is	  
retained	   on	   a	   subset	   of	   important	   developmental	   regulators,	  most	   likely	   deposited	   by	   Ezh1-­‐PRC2.	  
Indeed,	   knockdown	   of	   Eed	   in	   the	   Ezh2-­‐deficient	   cells	   diminishes	   the	   remaining	   H3K27me3	   and	  
prohibits	   reprogramming	   (Fragola	   et	   al.,	   2013).	   Another	   important	   aspect	   to	   consider	   is	   the	  
potentially	   distinct	   requirements	   of	   repressive	   complexes	   during	   early	   and	   late	   stages	   of	  
reprogramming	  (Ho	  et	  al.,	  2013)	  as	  well	  as	  effects	  on	  proliferation,	  which	  are	  not	  directly	   linked	  to	  
the	  acquisition	  of	  pluripotency,	  yet	  would	  still	  influence	  reprogramming	  efficiency.	  	  
	  
While	  the	  PRCs	  are	  observed	  to	  positively	  influence	  reprogramming,	  the	  opposite	  situation	  has	  been	  
reported	  for	  other	  repressive	  chromatin	  regulators.	  Recently,	  depletion	  of	  the	  core	  NuRD	  component	  
Mbd3	  was	   shown	   to	   increase	   the	  efficiency	  of	   iPSC	  generation	   (Luo	  et	  al.,	  2013;	  Rais	  et	  al.,	  2013).	  
One	  explanation	  for	  the	  seemingly	  discrepant	  roles	  of	  these	  repressor	  complexes	  might	  be	  that	  PRCs	  
are	   primarily	   involved	   in	   repression	   of	   differentiation-­‐associated	   genes,	   while	   NuRD	   also	   plays	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important	  roles	  in	  the	  regulation	  of	  pluripotency-­‐associated	  genes.	  In	  contrast,	  however,	  a	  separate	  
study	   shows	   that	  Mbd3	   is	   required	   for	   the	  establishment	  of	   iPSC	   from	  mouse	  neural	   stem	  cells	   as	  
well	   as	   the	  more	   primed	   epiblast	   stem	   cells	   and	   preiPSCs,	  while	   ectopic	   expression	   of	  Mbd3	  with	  
Nanog	  promotes	  reprogramming	  (dos	  Santos	  et	  al.,	  2014,	   in	  press).	  These	  discrepancies	  might	  stem	  
from	   differences	   in	   the	   experimental	   approaches	   and	   culture	   conditions	   applied,	   underlining	   the	  
context-­‐dependent	  nature	  of	  such	  studies.	  
	  
Collectively,	  a	  plethora	  of	  studies	  demonstrate	  important	  roles	  of	  chromatin	  repressive	  complexes	  in	  
governing	   cell	   identity	   and	   guarding	   the	   pluripotent	   state	   of	   ESCs.	   Tables	   1	   and	   2	   summarize	   the	  
observed	   phenotypes	   of	   loss-­‐of-­‐function	   studies	   concerning	   repressive	   complexes	   components	   in	  
pluripotent	  cells.	  
	  
Chromatin	  Repressive	  Complexes	  in	  Tissue	  Stem	  Cells	  and	  Development	  
During	  embryonic	  development,	  the	  chromatin	  environment	   is	  modulated	  to	  facilitate	  specification	  
and	  maintenance	  of	   the	  various	  cell	   types.	  Accordingly,	  many	  components	  of	  chromatin	   repressive	  
complexes	   are	   required	   for	   normal	   development.	   The	   exact	   phenotypes	   vary	   according	   to	   the	  
specific	   component	   investigated,	  but	   general	   features	   include	  defects	   in	  early	   lineage	   specification	  
upon	  knockout	  of	  Ring1b	  or	  core	  PRC2	  members	  (Faust	  et	  al.,	  1995;	  O'Carroll	  et	  al.,	  2001;	  Pasini	  et	  
al.,	  2004;	  Voncken	  et	  al.,	  2003)	  and	  several	  members	  of	  HDAC1/2-­‐containing	  complexes	  (Cowley	  et	  
al.,	  2005;	  David	  et	  al.,	  2003;	  Hendrich	  et	  al.,	  2001;	  Lagger	  et	  al.,	  2002;	  Wang	  et	  al.,	  2007a)	  as	  well	  as	  
later	   developmental	   problems	   with	   defects	   in	   cell	   type	   specification	   and	   tissue	   development	   as	  
observed	  for	  several	  components.	  In	  the	  context	  of	  PRC2,	  it	  is	  noteworthy	  that	  Jarid2	  knockout	  leads	  
to	  defects	   in	   neural	   tube	   formation	  with	   embryonic	   lethality	   around	  E15.5	   (Takeuchi	   et	   al.,	   1995),	  
while	  Pcl2	   knockout	  mice	   display	   an	   incompletely	   penetrant	   phenotype	   of	   skeletal	   transformation	  
(Wang	   et	   al.,	   2007b),	   providing	   evidence	   that	   neither	   interacting	   protein	   is	   solely	   responsible	   for	  
PRC2	  recruitment.	  
	  
Interestingly,	   the	   existence	   of	  multiple	   homologs	   of	   certain	   components	   appears	   to	   provide	   some	  
functional	   redundancy	   during	   development.	   For	   instance,	   mice	   lacking	   the	   PRC1	   component	  
Pcgf2/Mel18	   or	   the	   closely	   related	   gene	   Pcgf4/Bmi1	   are	   viable	   with	   homeotic	   transformations	  
(Akasaka	  et	  al.,	  1996;	  van	  der	  Lugt	  et	  al.,	  1994),	  while	  concomitant	  deletion	  of	  both	  genes	   leads	  to	  
embryonic	   lethality	   around	   E9.5	   (Akasaka	   et	   al.,	   2001).	   In	   the	   context	   of	   multiple	   homologs,	  
important	   factors	   to	   consider	   include	   spatiotemporal	   expression	   patterns	   as	   well	   as	   potential	  
distinctive	  functions	  of	  the	  homologous	  proteins,	  which	  can	  give	  rise	  to	  distinct	  phenotypes	  of	  loss	  of	  
single	  homologs.	  This	  is	  exemplified	  by	  the	  fact	  that	  knockout	  of	  Ezh2,	  Ring1b,	  Hdac1	  or	  Sin3a	  leads	  
to	   early	   embryonic	   lethality,	   while	   the	   loss	   of	   their	   closely	   related	   structural	   homologs	   have	   less	  
severe	   consequences	   on	   development.	   The	   observed	   phenotypes	   from	   knockout	   studies	   of	  
components	   of	   Polycomb	   group	   proteins	   and	   HDAC1/2-­‐containing	   complexes	   are	   summarized	   in	  
Tables	  1	  and	  2.	  	  
	  
In	  addition	  to	  their	  roles	  during	  early	  embryonic	  development,	  chromatin	  repressive	  complexes	  play	  
important	  roles	   in	  maintaining	  gene	  expression	  patterns	  and	  cell	   identity	  of	  many	  different	  tissues.	  
The	   roles	   of	   PRCs	   and	   HDAC1/2-­‐containing	   complexes	   in	   tissue	   stem	   cells	   and	   development	   are	  
discussed	  below	  and	  summarized	  in	  Supplementary	  Tables	  1	  and	  2.	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Polycomb	  Repressive	  Complexes	  in	  Tissue	  Stem	  Cells	  and	  Development	  
The	   PRCs	   have	   been	   most	   extensively	   studied	   in	   mESCs,	   but	   a	   growing	   number	   of	   studies	  
demonstrate	   important	   roles	   of	   PRCs	   in	   tissue-­‐specific	   stem	   and	   progenitor	   cells	   and	   conditional	  
knockout	  studies	  show	  that	  the	  PRCs	  are	  required	  during	  many	  aspects	  of	  mammalian	  development.	  	  
	  
In	   the	  hematopoietic	   system,	  Bmi1	   is	   required	   for	   self-­‐renewal	  of	   hematopoietic	   stem	  cells	   (HSCs)	  
through	  a	  mechanism	   involving	   the	   repression	  of	   the	   Ink4a-­‐Arf	   locus	   (Park	  et	   al.,	   2003),	   and	  Bmi1	  
knockout	   promotes	   premature	   and	   deficient	   lymphocytic	   specification	   (Oguro	   et	   al.,	   2010).	  
Interestingly,	   the	   specific	   composition	   of	   PRC1	   with	   regards	   to	   the	   Cbx	   component	   seems	   to	   be	  
important	  for	  the	  transition	  from	  self-­‐renewal	  to	  differentiation	  during	  hematopoiesis.	  As	  in	  mESCs,	  
Cbx7	  is	  required	  for	  HSC	  self-­‐renewal,	  while	  Cbx2/4/8-­‐containing	  PRC1	  seems	  to	  be	  important	  during	  
differentiation	  (Klauke	  et	  al.,	  2013).	  In	  addition,	  overexpression	  of	  Cbx7	  or	  Kdm2b	  promotes	  HSC	  self-­‐
renewal	  and	  the	  number	  of	  colony-­‐forming	  cells	  during	  serial	   transplantations	   (Klauke	  et	  al.,	  2013;	  
Konuma	  et	  al.,	   2011).	   Studies	  of	  PRC2	   in	   the	  hematopoietic	   system	  show	   that	  Ezh2	   is	   required	   for	  
normal	   lymphopoiesis	   (Su	   et	   al.,	   2003),	   and	   PRC2	   is	   involved	   in	   HSC	   self-­‐renewal	  with	   Ezh2	   being	  
important	   for	   HSC	   self-­‐renewal	   during	   fetal	   liver	   hematopoiesis,	   while	   Ezh1	   maintains	   the	   HSC	  
compartment	   in	   the	  adult	  bone	  marrow	   (Hidalgo	  et	  al.,	  2012;	  Mochizuki-­‐Kashio	  et	  al.,	  2011),	  once	  
again	  highlighting	  the	  importance	  of	  context-­‐specific	  incorporation	  of	  different	  homologs.	  Given	  the	  
many	  recent	  reports	  of	  increased	  expression	  levels	  and	  loss-­‐of-­‐function	  mutations	  of	  PRC2	  members	  
as	   well	   as	   hyperactive	   oncogenic	   EZH2	   mutants	   in	   hematopoietic	   cancers,	   it	   is	   highly	   relevant	   to	  
further	  study	  the	  role	  of	  PRCs	  in	  normal	  and	  malignant	  hematopoiesis.	  
	  
PRCs	  also	  contribute	  the	  self-­‐renewal	  capacity	  of	  neural	  stem	  cells	  by	  maintaining	  the	  Ink4a-­‐Arf	  locus	  
in	   a	   repressed	   state	   (Molofsky	   et	   al.,	   2003),	   and	   they	   are	   involved	   in	   the	   timely	   repression	   of	  
neurogenic	  factors,	  promoting	  the	  neurogenic-­‐to-­‐astrogenic	  switch	  (Hirabayashi	  et	  al.,	  2009;	  Roman-­‐
Trufero	  et	  al.,	  2009).	  Important	  roles	  of	  the	  PRCs	  have	  also	  been	  described	  in	  epidermal	  stem	  cells,	  
skeletal	  and	  cardiac	  muscle,	  hepatic	  stem	  cells	  and	  in	  the	  skeletal	  system	  (Supplementary	  Table	  1).	  
	  
While	  many	  studies	  have	  shown	  the	  requirement	  of	  PRCs	  for	  maintaining	  the	  differentiation	  capacity	  
of	  both	  mESCs	  and	  tissue-­‐specific	  stem	  cells,	  PRC	  components	  appear	  to	  be	  specifically	  required	  for	  
self-­‐renewal	  of	  a	  wide	  range	  of	  tissue-­‐specific	  stem	  cells.	  The	  basis	  for	  this	  differential	  requirement	  is	  
not	  entirely	  clear,	  but	  the	  consideration	  of	  several	  factors	  could	  provide	  some	  explanation:	  The	  use	  
of	  defined	  media	  and	  culture	  conditions	  might	  influence	  the	  outcome	  of	  loss-­‐of-­‐function	  studies,	  as	  
illustrated	  by	  the	  fact	  that	  some	  of	  the	  phenotypes	  observed	  in	  mESCs	  grown	  in	  serum/LIF	  have	  been	  
refuted	   by	   the	   introduction	   of	   2i/LIF-­‐based	   medium	   yielding	   more	   homogenous	   cell	   populations	  
influenced	  by	   fewer	  environmental	  cues.	  Furthermore,	   lineage-­‐committed	  tissue-­‐specific	  stem	  cells	  
residing	   in	   more	   complex	   and	   heterogeneous	   environments	   or	   grown	   in	   less	   well-­‐defined	   media	  
outside	  their	  niche	  might	  be	  more	  sensitive	  to	  the	  loss	  of	  chromatin	  factors.	  During	  differentiation,	  
the	   chromatin	   environment	   changes	   to	   a	   more	   restrictive	   conformation	   with	   accumulation	   of	  
repressive	   chromatin	   marks	   such	   as	   H3K27me3	   (Zhu	   et	   al.,	   2013).	   In	   the	   context	   of	   lineage-­‐
committed	  cells,	  loss	  of	  PRC2	  would	  influence	  this	  organization,	  leading	  to	  failures	  in	  differentiation	  
and/or	  altering	  developmental	  potential,	  as	  illustrated	  by	  the	  enhanced	  plasticity	  observed	  in	  Ezh2-­‐
deficient	  T	  cells	  (Tumes	  et	  al.,	  2013).	  	  
	  
Hdac1/2-­‐Containing	  Complexes	  in	  Tissue	  Stem	  Cells	  and	  Development	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While	  Hdac1/2	   are	   considered	   to	   act	   redundantly	   in	  most	   cell	   types,	   important	   exceptions	   to	   this	  
view	   include	   distinct	   roles	   during	   early	   embryogenesis,	   where	   Hdac1	   is	   essential	   and	   required	   for	  
proliferation	  through	  repression	  of	  cell	  cycle	  inhibitors	  (Lagger	  et	  al.,	  2002).	  In	  addition,	  conditional	  
knockout	   studies	   with	   combinatorial	   ablation	   of	   Hdac1/2	   demonstrate	   distinct	   roles	   during	  
epidermal	   development,	  where	   loss	   of	   a	   single	   allele	   of	  Hdac2	   in	   an	  Hdac1	   knockout	   background	  
leads	   to	   developmental	   defects	   (Winter	   et	   al.,	   2013),	   and	   the	   opposite	   situation	   in	   neuronal	  
development,	   where	   Hdac1	   haplo-­‐insuffiency	   is	   observed	   in	   Hdac2	   knockouts	   (Hagelkruys	   et	   al.,	  
2014).	  
	  
Studies	  in	  knockout	  mice	  and	  tissue-­‐specific	  stem	  cells	  show	  important	  roles	  of	  Hdac1/2-­‐containing	  
complexes	  in	  many	  different	  tissues,	  including	  roles	  of	  NuRD,	  Sin3	  and	  CoREST	  in	  the	  hematopoietic	  
system	  (Cowley	  et	  al.,	  2005;	  David	  et	  al.,	  2008;	  Kerenyi	  et	  al.,	  2013;	  Williams	  et	  al.,	  2004;	  Yao	  et	  al.,	  
2014;	  Yoshida	  et	  al.,	  2008;	  Zhang	  et	  al.,	  2012b),	  roles	  of	  NuRD	  in	  epidermal	  stem	  cells	  (Kashiwagi	  et	  
al.,	  2007),	  and	   roles	  of	  REST/CoREST	  and	  Lsd1	   in	  neural	   stem	  cells	  and	  during	  neural	  development	  
(Qureshi	  et	  al.,	  2010;	  Sun	  et	  al.,	  2010;	  Wang	  et	  al.,	  2007a)	  (Supplementary	  Table	  2).	  
	  
Taken	   together,	   chromatin	   repressive	  complexes	  are	  essential	   for	  establishing	  and	  maintaining	  cell	  
identity	   during	   tissue	   development	   and	   homeostasis,	   in	   part	   through	   their	   ability	   to	   restrict	   the	  
expression	  of	  important	  cell	  cycle	  regulators	  and	  key	  developmental	  genes.	  One	  emerging	  picture	  is	  
that	   subunit	   composition	   and	   association	   with	   specific	   interactors	   provide	   important	   means	   for	  
regulating	   the	   function	  of	   the	   complexes	   in	  different	   cell	   types	  and	  developmental	   stages.	   Further	  
elucidation	  of	  the	  molecular	  basis	  of	  tissue-­‐specific	  functions	  of	  repressor	  complexes	  will	  be	  crucial	  
for	  understanding	  the	  consequence	  of	  their	  deregulation	  in	  cancer.	  
	  
Chromatin	  Repressive	  Complexes	  in	  Cancer	  
Many	  cancers	  display	  a	  dedifferentiated	  stem	  cell-­‐like	  phenotype,	  and	  several	  of	  the	  factors	  required	  
for	   establishing	   or	  maintaining	   stem	   cell	   states	   are	   also	   involved	   in	   oncogenesis.	   Thus,	   bearing	   in	  
mind	  that	  chromatin	  repressors	  are	  crucial	  for	  establishing	  and	  preserving	  cellular	  identity,	  it	  is	  to	  be	  
expected	   that	   chromatin	   repressors	  would	   often	   be	   found	   deregulated	   in	   human	   cancers.	   Intense	  
research	   is	   going	   into	   elucidating	   the	  mechanism	  by	  which	   chromatin	  modifiers	   and	  modifications	  
promote	   cancer	   development	   or	   progression.	   One	   of	   the	   early	   recurring	   questions	   in	   cancer	  
epigenetics	   was	   that	   of	   “cause	   or	   consequence”,	   that	   is,	   whether	   the	   chromatin	   environment	   is	  
deregulated	  as	  a	  consequence	  of	  the	  cancer	  or	  if	  the	  chromatin	  regulators	  play	  a	  direct	  role	  in	  driving	  
oncogenesis.	   However,	   recent	   discoveries	   of	   copious	   numbers	   of	   recurrent	   somatic	   mutations	   in	  
genes	  encoding	  chromatin-­‐associated	  proteins	  argue	  that	  a	  deregulated	  chromatin	  environment	  can	  
play	  a	  causal	   role	   in	   the	  disease	   (You	  and	   Jones,	  2012).	   In	   the	   following,	  we	  will	  discuss	   reports	  of	  
deregulated	   chromatin	   repressors	   as	   well	   as	   their	   emerging	   roles	   as	   targets	   for	   anti-­‐cancer	  
therapeutics.	  	  
	  
Polycomb	  Repressive	  Complexes	  and	  Cancer	  
Increased	  levels	  of	  EZH2	  have	  been	  correlated	  with	  poor	  outcome	  in	  metastatic	  prostate	  cancer	  and	  
poor	   prognosis	   in	   tumors	   of	   other	   tissues	   (Bracken	   et	   al.,	   2003;	   Kleer	   et	   al.,	   2003;	   Takawa	   et	   al.,	  
2011;	  Varambally	  et	  al.,	  2002;	  Wagener	  et	  al.,	  2010).	  Recently,	  recurrent	  point	  mutations	  in	  the	  SET	  
domain	   of	   EZH2	   have	   been	   described	   in	   diffuse	   large	   B	   cell	   lymphoma	   and	   follicular	   lymphoma,	  
conferring	  hyperactivity	  of	  EZH2	  yielding	  increased	  levels	  of	  H3K27me3	  (Beguelin	  et	  al.,	  2013;	  Lohr	  et	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al.,	   2012;	   McCabe	   et	   al.,	   2012a;	   Morin	   et	   al.,	   2010;	   Pasqualucci	   et	   al.,	   2011;	   Ryan	   et	   al.,	   2011).	  
Further	  evidence	  for	  direct	  roles	  of	  H3K27	  methylation	  in	  cancer	  includes	  loss-­‐of-­‐function	  mutations	  
of	  the	  demethylase	  UTX	  (Dalgliesh	  et	  al.,	  2010;	  van	  Haaften	  et	  al.,	  2009)	  and	  the	  recent	  discoveries	  of	  
somatic	  mutations	  of	  lysine	  27	  in	  H3.3	  in	  pediatric	  glioblastoma	  (Schwartzentruber	  et	  al.,	  2012;	  Wu	  
et	   al.,	   2012).	   However,	   this	   mutation	   has	   been	   shown	   to	   inhibit	   PRC2	   activity,	   leading	   to	   lower	  
H3K27me3	  levels.	  Loss-­‐of-­‐function	  mutations	  of	  EZH2	  as	  well	  as	  SUZ12,	  EED	  and	  JARID2	  have	  been	  
identified	  in	  myeloid	  cancers	  (Ernst	  et	  al.,	  2010;	  Nikoloski	  et	  al.,	  2010;	  Puda	  et	  al.,	  2012;	  Ueda	  et	  al.,	  
2012)	  and	  T-­‐ALL	  (Ntziachristos	  et	  al.,	  2012;	  Simon	  et	  al.,	  2012;	  Zhang	  et	  al.,	  2012a)	  as	  well	  as	  cancers	  
of	   other	   tissues.	   Thus,	   the	   role	   of	   PRC2	   in	   cancer	   is	   highly	   context	   dependent	  with	   EZH2	   exerting	  
functions	  as	  an	  oncogene	  as	  well	  as	  a	  tumor	  suppressor.	  
	  
Indications	  of	  PRC1	   involvement	   in	  human	  cancer	   include	   increased	  expression	   levels	  of	  BMI1	  and	  
correlation	  with	  poor	  prognosis	  in	  a	  range	  of	  solid	  tumors	  and	  hematological	  cancers	  (He	  et	  al.,	  2009;	  
Mohty	  et	  al.,	  2007;	  Nowak	  et	  al.,	  2006;	  Shafaroudi	  et	  al.,	  2008)	  and	  reports	  of	  oncogenic	  functions	  of	  
CBX7	   in	   the	   hematopoietic	   system	   (Klauke	   et	   al.,	   2013;	   Scott	   et	   al.,	   2007)	   and	   some	   solid	   tumors	  
(Shinjo	   et	   al.,	   2013;	   Zhang	   et	   al.,	   2010)	   as	  well	   as	   tumor	   suppressor	   roles	   in	   others	   (Forzati	   et	   al.,	  
2012).	  	  	  
	  
HDAC1/2-­‐Containing	  Complexes	  and	  Cancer	  
While	  somatic	  mutations	  in	  HDACs	  are	  rare,	  there	  are	  many	  reports	  of	  HDAC1/2	  being	  overexpressed	  
in	   human	   cancers,	   often	   correlating	  with	   poor	   patient	   outcome.	   In	   contrast,	   there	   is	   also	   data	   on	  
cancer-­‐associated	   loss-­‐of-­‐function	  mutations	   of	   HDAC1/2,	   and	   knockout	  mouse	  models	   show	   that	  
these	   proteins	   can	   also	   exert	   tumor	   suppressive	   roles	   (West	   and	   Johnstone,	   2014).	   In	   addition,	  
HDACs	  are	  aberrantly	   recruited	   to	   target	  genes	   in	  many	  cancers,	   in	  part	  due	   to	  altered	  expression	  
level	  of	  specific	  subunits	  of	   the	  HDAC-­‐containing	  complexes.	  The	  SIN3-­‐associated	  protein	  BRMS1	   is	  
often	   lost	   in	   invasive	   stages	   of	   human	   cancers	   (Hurst,	   2012),	   and	   ING1/2	   are	   often	   mutated	   or	  
downregulated	   in	   human	   cancers,	   pointing	   to	   tumor	   suppressive	   roles	   of	   SIN3	   (Guerillon	   et	   al.,	  
2014).	   The	  MTA	   subunits	   are	   the	  most	   studied	   components	  of	  NuRD	  with	   a	   role	   in	   cancer.	  As	   the	  
name	   implies,	   MTA1	   (metastasis	   associated	   gene	   1)	   was	   originally	   identified	   by	   its	   preferential	  
expression	   in	   a	   metastatic	   tumor	   model,	   and	   increased	   expression	   in	   a	   wide	   range	   of	   tumors	  
correlates	   with	   tumor	   grade	   and	   poor	   prognosis	   (Nicolson	   et	   al.,	   2003).	   Interestingly,	   there	   is	   an	  
inverse	   correlation	   between	   MTA1	   and	   MTA3	   expression	   during	   cancer	   progression,	   and	   MTA3	  
seems	   to	   play	   mainly	   tumor	   suppressive	   functions,	   thus	   pointing	   to	   the	   importance	   of	   specific	  
subunit	  composition	  in	  regulating	  complex	  function	  (Lai	  and	  Wade,	  2011).	  ZNF217	  is	  overexpressed	  
in	   cancers	   and	  was	   found	   to	   recruit	   CoREST	   to	   the	   INK4B	   locus	   (Thillainadesan	   et	   al.,	   2012),	   thus	  
promoting	  proliferation,	  and	  LSD1	  expression	  is	  elevated	  in	  many	  human	  cancers	  (Helin	  and	  Dhanak,	  
2013),	   but	   is	   also	   reported	   to	   be	   downregulated	   and	   involved	   in	   the	   suppression	   of	  metastasis	   in	  
breast	  cancers	  (Wang	  et	  al.,	  2009b).	  Whether	  LSD1	  exerts	  its	  functions	  in	  cancer	  mainly	  as	  a	  subunit	  
of	  NuRD,	  CoREST	  or	  along	  with	  additional	  factors	  remains	  to	  be	  elucidated.	  
	  
Molecular	  Mechanisms	  of	  Chromatin	  Repressive	  Complexes	  in	  Cancer	  
The	  mechanisms	   by	   which	   repressive	   complexes	   proteins	   contribute	   to	   oncogenesis	   include	   their	  
roles	  in	  repressing	  genes	  activated	  by	  stress	  signals	  and	  involved	  in	  proliferation.	  PcG	  proteins	  bind	  
the	   INK4A-­‐ARF-­‐INK4B	   locus	   and	   overexpression	   of	   PcG	   proteins	   prevents	   expression	   of	   p14	   (ARF),	  
p15	  (INK4B)	  and	  p16	  (INK4A)	  in	  response	  to	  stress	  signals,	  including	  oncogenes	  (Bracken	  et	  al.,	  2007).	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While	   cancer	   cells	  generally	  display	  global	  DNA	  hypomethylation,	  CpG	   islands	  of	   tumor	   suppressor	  
genes	  are	  often	  aberrantly	  methylated	   in	   cancer.	   Interestingly,	  PcG	  binding	  has	  been	   suggested	   to	  
predispose	   promoters	   for	   DNA	   hypermethylation	   (Ohm	   et	   al.,	   2007;	   Schlesinger	   et	   al.,	   2007;	  
Widschwendter	  et	  al.,	  2007).	  Oncogenic	  fusion	  proteins	  have	  been	   implicated	   in	  aberrant	  targeting	  
of	  repressive	  complexes	  to	  chromatin,	  including	  PLZF-­‐RARα-­‐mediated	  recruitment	  of	  PRC1	  and	  PML-­‐
RARα-­‐mediated	  recruitment	  of	  PRC2,	  DNMTs	  and	  NuRD	  in	  leukemia	  (Lai	  and	  Wade,	  2011;	  Richly	  et	  
al.,	  2011).	  NuRD,	  LSD1	  and	  PcG	  proteins	  have	  been	  shown	  to	  promote	  the	  epithelial-­‐to-­‐mesenchymal	  
transition	   (EMT)	   through	   TWIST-­‐	   or	   SNAIL1-­‐mediated	   downregulation	   of	   E-­‐cadherin	   (Tam	   and	  
Weinberg,	  2013),	  and	  EZH2	  overexpression	  seems	  to	  promote	  tumor	  angiogenesis	  (Lu	  et	  al.,	  2010).	  
Another	   important	   aspect	   is	   the	   role	   of	   repressive	   complexes	   in	   governing	   cell	   identity:	   indeed,	  
aberrant	   expression	   of	   PcG	   proteins	   helps	   sustaining	   a	   dedifferentiated	   phenotype	   as	   seen	   for	  
instance	   in	   rhabdomyosarcoma,	   where	   knockdown	   studies	   and	   application	   of	   specific	   inhibitors	  
targeting	  EZH2	   is	  able	   to	  partially	   reinstate	  muscle	  cell	   identity	   to	   the	   tumor	  cells	   (Marchesi	  et	  al.,	  
2012).	  
	  
Although	   the	   involvement	   of	   chromatin	   repressive	   complexes	   in	   cancer	   is	   indisputable,	   their	  
functional	   role	   in	  oncogenesis	   is	  still	   incompletely	  understood	  as	   they	  promote	  oncogenesis	   in	  one	  
setting,	  while	  protecting	  against	  malignant	  transformation	  in	  another.	  This	  duality	  is	  probably	  related	  
to	  the	  role	  of	  chromatin	  modifiers	  in	  modulating	  transcriptional	  output	  of	  target	  genes	  with	  opposing	  
functions.	   Rather	   than	   directly	   deciding	   the	   transcription	   programs,	   alterations	   in	   the	   level	   of	  
chromatin	   regulators	   changes	   the	   threshold	   for	   transcriptional	   activation	   or	   repression	   and	   this	  
altered	   chromatin	   balance	   sensitizes	   the	   cell	   to	   stimuli	   promoting	   oncogenic	   transformation.	  
Deciphering	  the	  role	  of	  repressive	  complexes	  in	  specific	  cancer	  types	  will	  be	  important	  for	  furthering	  
our	  understanding	  and	  guiding	  new	  therapies.	  
	  
Targeting	  Chromatin	  Repressive	  Complexes	  in	  Cancer	  
While	   genetic	   lesions	   are	   difficult	   to	   target	   therapeutically,	   targeting	   the	   deregulated	   chromatin	  
environment	   is	   tempting	   due	   to	   the	   reversibility	   of	   the	   system.	   Several	   drugs	   targeting	   chromatin	  
modifiers	  are	  already	  being	  used	  in	  the	  clinic.	  Most	  famously,	  DNA	  methyltransferase	  inhibitors	  are	  
used	   to	   treat	   patients	   with	   MDS,	   where	   they	   prolong	   life	   span	   and	   prevent	   the	   progression	   to	  
leukemia	  (Helin	  and	  Dhanak,	  2013).	  
	  
HDAC	  Inhibitors	  
Another	   class	  of	  molecules	   already	  being	  used	   in	   the	   clinic	   is	  HDAC	   inhibitors,	  which	  are	   currently	  
used	  in	  the	  treatment	  of	  T-­‐cell	  lymphoma.	  The	  FDA-­‐approved	  Vorinostat	  and	  Romidepsin	  target	  Class	  
I	  HDACs	  and	  are	  able	   to	   inhibit	   the	   function	  of	  HDAC1/2	   in	   the	  context	  of	  SIN3,	  NuRD	  and	  CoREST	  
(Khan	  and	  La	  Thangue,	  2012;	  West	  and	  Johnstone,	  2014).	  The	  molecular	  mechanisms	  of	  these	  drugs	  
are	  still	   incompletely	  understood,	  but	  treatment	  outcomes	   include	  cell	  cycle	  arrest	  via	   induction	  of	  
p21,	  increased	  apoptosis,	  anti-­‐angiogenic	  effects	  via	  HIF1	  inhibition	  as	  well	  as	  sensitization	  of	  cancer	  
cells	  to	  DNA	  damaging	  agents	  (Khan	  and	  La	  Thangue,	  2012).	  Despite	  these	  encouraging	  results,	  there	  
is	   no	   clear	   correlation	   between	   acetylation	   levels	   and	   clinical	   outcome	   upon	   HDAC	   inhibition.	   In	  
addition,	  it	  has	  been	  difficult	  to	  establish	  robust	  biomarkers	  to	  predict	  efficacy,	  and,	  thus	  far,	  these	  
drugs	  are	  limited	  to	  treatment	  of	  specific	  hematological	  cancers	  (Helin	  and	  Dhanak,	  2013).	  
	  
LSD1	  Inhibitors	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In	   addition	   to	   HDAC	   inhibitors,	   LSD1	   inhibition	   represents	   a	   potential	   novel	   route	   of	   targeting	  
complexes	  such	  as	  NuRD	  and	  CoREST.	  Two	  recent	  studies	  have	  provided	  evidence	  for	  an	  important	  
role	   of	   LSD1	   in	   acute	   myeloid	   leukemia	   (Harris	   et	   al.,	   2012;	   Schenk	   et	   al.,	   2012).	   Neither	   study	  
observes	  any	  global	  effect	  on	  histone	  methylation,	  but	  both	  report	  localized	  increases	  in	  H3K4me2	  at	  
specific	   promoters,	   including	   the	   differentiation	   marker	   CD11b	   (Schenk	   et	   al.,	   2012),	   and	   certain	  
MML-­‐AF9	  targets	  (Harris	  et	  al.,	  2012).	  These	  studies	  raise	  several	  questions	  regarding	  the	  function	  of	  
LSD1	   in	   leukemia:	  First,	  LSD1	  binds	   throughout	   the	  genome	  as	  part	  of	  several	  different	  complexes,	  
yet	  the	  effects	  on	  H3K4me2	  are	  very	  localized.	  Second,	  while	  LSD1	  inhibition	  leads	  to	  an	  increase	  in	  
CD11b	  expression	  (Schenk	  et	  al.,	  2012),	  the	  increased	  H3K4me2	  at	  MML-­‐AF9	  target	  genes	  is	  actually	  
accompanied	  by	  lower	  expression	  (Harris	  et	  al.,	  2012),	  which	  is	  surprising	  considering	  that	  H3K4me2	  
is	   usually	   associated	   with	   gene	   expression.	   Thus,	   while	   these	   studies	   are	   encouraging,	   the	  
mechanisms	   underlying	   the	   differentiation	   and	   apoptosis-­‐inducing	   properties	   of	   LSD1	   inhibitors	  
remain	  to	  be	  elucidated.	  	  
	  
EZH2	  Inhibitors	  
With	   EZH2	   being	   overexpressed	   in	   many	   cancers	   and	   the	   recent	   reports	   on	   hyperactive	   EZH2	  
mutants	   in	   follicular	   lymphoma	   and	   diffuse	   large	   B-­‐cell	   lymphoma,	   specific	   EZH2	   inhibitors	   are	  
attracting	  interest	  as	  potential	  anti-­‐cancer	  drugs.	  Several	  highly	  selective	  compounds	  show	  promising	  
results	  in	  reducing	  H3K27me3	  levels,	  decreasing	  proliferation	  and	  increasing	  apoptosis	  in	  lymphoma	  
cell	   lines	   carrying	   SET	   domain	   mutations	   and	   markedly	   reducing	   tumor	   burden	   and	   increasing	  
survival	  in	  mouse	  xenograft	  models	  (Knutson	  et	  al.,	  2014;	  Knutson	  et	  al.,	  2012;	  McCabe	  et	  al.,	  2012b;	  
Qi	   et	   al.,	   2012),	   and	   two	   EZH2	   inhibitors	   have	   entered	   clinical	   trials	   (www.clinicaltrials.gov).	  
Interestingly,	   EZH2	   inhibition	   has	   also	   been	   shown	   to	   inhibit	   the	   growth	   of	   rhabdoid	   tumors	   and	  
lowering	   intra-­‐tumor	   levels	   of	   H3K27me3,	   potentially	   expanding	   the	   therapeutic	   range	   beyond	  
hematopoietic	  malignancies	   (Knutson	  et	  al.,	   2013).	  These	  pediatric	   tumors	  arise	   from	  a	   loss	  of	   the	  
SNF5	  component	  of	  the	  SWI/SNF	  remodeling	  complex	  (Versteege	  et	  al.,	  1998).	  They	  display	  elevated	  
EZH2	   levels,	  and	  conditional	  knockout	  of	  Ezh2	  has	  been	  shown	  to	  reduce	  tumor	  growth	  (Wilson	  et	  
al.,	   2010).	   Interestingly,	   this	   type	   of	   tumor	   only	   carries	   few	   somatic	   mutations	   (Lee	   et	   al.,	   2012),	  
potentially	  making	   them	  more	  dependent	  on	   the	  chromatin	  environment	  and	  one	  might	  speculate	  
that	   other	   tumor	   types	   with	   few	   somatic	   mutations	   could	   show	   similar	   vulnerability	   to	   PRC2	  
inhibitors.	  Importantly,	  despite	  clear	  effects	  on	  prohibiting	  cancer	  growth,	  it	  has	  not	  been	  possible	  to	  
identify	   consistent	   transcriptional	   profiles	   being	   reverted	   upon	   treatment	   with	   EZH2	   inhibitors	  
(McCabe	  et	  al.,	  2012b).	  This	  lack	  of	  consistency	  indicates	  that	  EZH2	  targets	  different	  pathways	  even	  
within	   the	   same	   types	   of	   tumors,	   in	   agreement	   with	   a	   role	   of	   chromatin	   factors	   in	   threshold	  
modulation	   as	   opposed	   to	   directly	   deciding	   the	   transcriptional	   outcome.	   With	   EZH2	   exhibiting	  
characteristics	  of	  an	  oncogene	  as	  well	  as	  a	   tumor	  suppressor	  even	  within	  hematological	  cancers,	   it	  
will	   be	   important	   to	   develop	   tools	   and	   biomarkers	   to	   predict	   efficacy	   of	   targeting	   EZH2	  
therapeutically	  and	  to	  stratify	  patients	  accordingly.	  	  
	  
Alternative	  Ways	  of	  Targeting	  Polycomb	  Repressive	  Complexes	  
In	  the	  context	  of	  targeting	  PcG	  proteins	  in	  cancer,	  several	  new	  drugs	  are	  currently	  being	  tested.	  One	  
approach,	   targeting	   the	   EED-­‐EZH2	   interface	   by	   treatment	  with	   a	   stabilized	  α-­‐helix	   of	   EZH2,	   shows	  
disruption	  of	  PRC2	  complex	  formation,	  lower	  levels	  of	  H3K27me3,	  growth	  arrest	  and	  differentiation	  
of	  MLL-­‐AF9	  driven	  leukemic	  cells	   (Kim	  et	  al.,	  2013).	   In	  the	  context	  of	  targeting	  PRC1,	  application	  of	  
small-­‐molecule	  BMI1	  inhibitors	  reduced	  global	  H2AK119ub1	  in	  colorectal	  cancer	  cells	  and	  decreased	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tumor	   load	   in	   transplanted	  mice	   through	   a	   depletion	  of	   cancer-­‐initiation	   cells	   (Kreso	   et	   al.,	   2014).	  
Another	   potential	   approach	   to	   targeting	   PRC1	   is	   by	   chromodomain	   inhibitors	   targeting	   the	   CBX-­‐
component.	  Recently,	  Simhadri	  et	  al.	   reported	  on	  the	  development	  of	  a	  chromodomain	  antagonist	  
with	   10-­‐400	   fold	   selectivity	   for	   CBX7	   over	   other	   CBX	   family	   members	   (Simhadri	   et	   al.,	   2014).	   In	  
addition,	  studies	  of	  BET	  (bromodomain	  and	  extracellular)	  domain	  inhibitors	  targeting	  BRD4	  indicate	  
that	   targeting	   domains	   recognizing	   histone	  modifications	   is	   therapeutically	   feasible	   (Di	   Croce	   and	  
Helin,	   2013).	  With	   its	   oncogenic	   roles	   in	   the	   hematopoietic	   system	   and	   CBX7	   being	   preferentially	  
involved	  in	  undifferentiated	  cell	  types,	  it	  will	  be	  interesting	  to	  explore	  CBX7	  inhibition	  as	  a	  potential	  
novel	  strategy	  for	  targeting	  PRC1	  in	  cancer.	  
	  
Concluding	  Remarks	  
The	   chromatin	   environment	   is	   an	   important	   factor	   in	   the	   establishment	   and	   maintenance	   of	   cell	  
identity.	  Accordingly,	  the	  protein	  complexes	  modulating	  chromatin	  are	   important	  for	  many	  aspects	  
of	  mammalian	  development	  and	  stem	  cell	  function	  and	  are	  often	  deregulated	  in	  cancers.	  While	  the	  
introduction	   of	   DNA	   demethylating	   agents	   and	   HDAC	   inhibitors	   in	   the	   clinic	   provides	   proof-­‐of-­‐
concept	   of	   the	   feasibility	   of	   targeting	   the	   chromatin	   environment	   in	   cancer,	   and	   the	   ongoing	  
development	   of	   novel	   drugs	   targeting	   chromatin	   modifiers	   show	   promising	   results	   in	   pre-­‐clinical	  
trials,	  the	  mechanisms	  underlying	  their	  efficacy	  are	  not	  understood.	  Thus,	  further	  elucidation	  of	  the	  
role	   of	   chromatin	   repressive	   complexes	   in	   cancer	   and	   the	   development	   of	   robust	   predictive	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Table	  1.	  Loss-­‐of-­‐function	  phenotypes	  of	  Polycomb	  repressive	  complexes	  
	   Development	   mESCs	   Reprogramming	   References	  
PRC1	  
Ring1a	   Viable	  with	  homeotic	  transformation.	   	  
Knockdown	  impairs	  
reprogramming.	  
(del	  Mar	  Lorente	  et	  al.,	  
2000;	  Onder	  et	  al.,	  2012)	  
Ring1b	  
Lethal	  around	  E10.5.	  
Gastrulation	  defects	  and	  cell	  
cycle	  inhibition.	  
Global	  loss	  of	  H2AK119ub1.	  




(de	  Napoles	  et	  al.,	  2004;	  
Leeb	  and	  Wutz,	  2007;	  
Voncken	  et	  al.,	  2003)	  	  
Ring1a/Ring1b	  
double	  KO	   	  
Loss	  H2AK119ub1	  (also	  on	  Xi),	  
derepression	  of	  target	  genes,	  
loss	  of	  self-­‐renewal	  and	  
differentiation	  defects.	  	  
Knockout	  impairs	  
reprogramming.	  
(de	  Napoles	  et	  al.,	  2004;	  
Endoh	  et	  al.,	  2008;	  
Pereira	  et	  al.,	  2010)	  
Pcgf2	  (Mel18)	   Homeotic	  transformation,	  postnatal	  lethality.	   	   	   (Akasaka	  et	  al.,	  1996)	  
Pcgf4	  (Bmi1)	  
Homeotic	  transformation,	  
neurological	  and	  immune	  






(Moon	  et	  al.,	  2011;	  Onder	  
et	  al.,	  2012;	  van	  der	  Lugt	  
et	  al.,	  1994)	  
Pcgf2/	  Pcgf4	  
double	  KO	   Lethal	  around	  E9.5.	   	   	   (Akasaka	  et	  al.,	  2001)	  
Cbx2	  (M33)	  
Homeotic	  transformation	  and	  
severe	  immune	  defects.	  50	  %	  
die	  perinatally.	  Remaining	  
pups	  die	  postnatally.	  
	   	   (Core	  et	  al.,	  1997)	  
Cbx4	   Perinatal	  lethality	  with	  severe	  immune	  defects.	   	   	   (Liu	  et	  al.,	  2013)	  
Cbx7	  
Increased	  susceptibility	  to	  
tumors	  of	  liver	  and	  lung.	  
	   	   (Forzati	  et	  al.,	  2012)	  
	   Knockdown	  yields	  
differentiation	  defects.	  
	   (Morey	  et	  al.,	  2012)	  
Phc1	  (Rae28)	   Perinatal	  lethality	  and	  
homeotic	  transformation.	  
	   	   (Takihara	  et	  al.,	  1997)	  
Phc2	   Viable	  with	  homeotic	  transformation.	   	   	   (Isono	  et	  al.,	  2005)	  
Phc1/2	  	  
double	  KO	   Lethal	  before	  E11.5.	   	   	   (Isono	  et	  al.,	  2005)	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Rybp	   Early	  postimplantation	  lethality	  around	  E6.5.	  
Knockdown	  yields	  reduction	  
of	  H2AK119ub1	  and	  
differentiation	  defects.	  
	   (Gao	  et	  al.,	  2012;	  Pirity	  et	  al.,	  2005)	  




	   (Qin	  et	  al.,	  2012)	  
Kdm2b	  (Fbxl10)	  
Incompletely	  penetrant	  peri-­‐
/postnatal	  lethality	  with	  
defects	  in	  neural	  tube	  closure.	  	  
Knockdown	  yields	  reduction	  





(Fukuda	  et	  al.,	  2011;	  
Liang	  et	  al.,	  2012;	  Wu	  et	  
al.,	  2013)	  
PRC2	  
Ezh2	   Lethal	  around	  E7.5-­‐8.5.	  Gastrulation	  defects.	  








knockout	  does	  not	  
impair	  mouse	  iPSC	  
formation.	  
(Buganim	  et	  al.,	  2012;	  
Fragola	  et	  al.,	  2013;	  
O'Carroll	  et	  al.,	  2001;	  
Onder	  et	  al.,	  2012;	  
Pereira	  et	  al.,	  2010;	  Shen	  
et	  al.,	  2008)	  
Ezh1	   	   	   Not	  required.	   (Onder	  et	  al.,	  2012)	  
Eed	   Lethal	  around	  E7.5-­‐8.5.	  
Gastrulation	  defects.	  
Global	  loss	  of	  H3K27me2/3,	  
slight	  derepression	  of	  target	  
genes	  and	  differentiation	  
defects.	  Late-­‐passage	  Eed-­‐/-­‐	  
cells:	  Global	  loss	  of	  




(Chamberlain	  et	  al.,	  2008;	  
Faust	  et	  al.,	  1998;	  Faust	  
et	  al.,	  1995;	  Montgomery	  
et	  al.,	  2005;	  Pereira	  et	  al.,	  
2010;	  Schumacher	  et	  al.,	  
1996)	  	  
Suz12	   Lethal	  around	  E7.5-­‐8.5.	  Gastrulation	  defects.	  




(Pasini	  et	  al.,	  2007;	  Pasini	  
et	  al.,	  2004;	  Pereira	  et	  al.,	  
2010)	  
Jarid2	  
Lethal	  at	  E11.5-­‐15.5	  with	  
developmental	  defects	  
depending	  on	  strain.	  
Differentiation	  defects.	   Not	  required.	  
(Lee	  et	  al.,	  2000;	  
Motoyama	  et	  al.,	  1997;	  
Pereira	  et	  al.,	  2010;	  Shen	  
et	  al.,	  2009;	  Takeuchi	  et	  
al.,	  1999;	  Takeuchi	  et	  al.,	  
1995)	  
Pcl2	  
Viable	  with	  incompletely	  
penetrant	  defects	  including	  
homeotic	  transformations.	  
Knockdown	  yields	  enhanced	  
self-­‐renewal	  and	  
differentiation	  defects.	  
	   (Walker	  et	  al.,	  2010;	  
Wang	  et	  al.,	  2007b)	  
Pcl3	  	   	   Knockdown	  yields	  differentiation	  defects.	   	   (Brien	  et	  al.,	  2012)	  
Yy1	   Peri-­‐implantation	  lethality.	  	   	   Knockdown	  enhances	  efficiency.	  
(Donohoe	  et	  al.,	  1999;	  




Table	  2.	  Loss-­‐of-­‐function	  phenotypes	  of	  Hdac1/2-­‐containing	  complexes	  
	   Development	   mESCs	   Reprogramming	   References	  
Hdac1/2	  
Hdac1	   Lethal	  E9.5-­‐10.5.	   Decreased	  proliferation	  and	  differentiation	  defects.	   	  
(Dovey	  et	  al.,	  2010;	  
Lagger	  et	  al.,	  2002)	  
Hdac2	   Perinatal	  lethality	  with	  cardiac	  malformations.	  
Not	  effect	  on	  self-­‐renewal	  or	  
pluripotency.	   	  
(Dovey	  et	  al.,	  2010;	  
Montgomery	  et	  al.,	  2007)	  
Hdac1/2	   	   	   Valproic	  acid	  increases	  
efficiency.	  
(Huangfu	  et	  al.,	  2008)	  
Sin3	  
Sin3a	   Periimplantation	  lethality.	   Insufficient	  outgrowth	  of	  ICM	  
during	  mESC	  establishment.	  
	   (Cowley	  et	  al.,	  2005;	  
Dannenberg	  et	  al.,	  2005)	  
Sin3b	   Perinatal	  lethality.	  Pups	  born	  
in	  submendelian	  ratios.	  
	   	   (David	  et	  al.,	  2008)	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Sds3	  
Periimplantation	  lethality.	  
Defects	  in	  chromosome	  
segregation	  and	  early	  lineage	  
specification.	  
	   	   (David	  et	  al.,	  2003)	  
NuRD	  
Mbd2	   Mice	  are	  viable.	  Abnormal	  maternal	  behavior.	   	   	   (Hendrich	  et	  al.,	  2001)	  




Knockout	  impairs	  and	  
ectopic	  expression	  
enhances	  efficiency.	  
(Hendrich	  et	  al.,	  2001;	  
Kaji	  et	  al.,	  2006;	  Luo	  et	  
al.,	  2013;	  Rais	  et	  al.,	  2013)	  
(dos	  Santos	  et	  al.,	  2014,	  in	  
press)	  
Gatad2a	   Postimplantation	  lethality,	  morphological	  defects.	   	   	   (Marino	  and	  Nusse,	  2007)	  
CoREST	  
CoREST	   Late	  embryonic	  lethality	  due	  
to	  severe	  anemia.	  
	   	   (Yao	  et	  al.,	  2014)	  
Lsd1	  
Early	  embryonic	  lethality	  
around	  E5.5	  with	  defects	  in	  
gastrulation	  and	  trophoblast	  
specification.	  	  
Reduced	  CoREST	  levels,	  slight	  
deregulation	  of	  gene	  
expression	  and	  differentiation	  
defects.	  
	  
(Foster	  et	  al.,	  2010;	  Wang	  
et	  al.,	  2009a;	  Wang	  et	  al.,	  





Figure	  1.	  Schematic	  representation	  of	  Polycomb	  repressive	  complexes.	  	  
Polycomb	  Repressive	  Complex	  2	  (PRC2)	  catalyzes	  methylation	  of	  H3K27	  (red	  circles).	  Several	  publications	  have	  
shown	   that	   PRC2	   recruitment	   relies	   on	   interacting	   proteins	   (such	   as	   JARID2,	   AEBP2	   and	   PCL1-­‐3),	   transient	  
interactions	  with	  cell-­‐type-­‐specific	  transcription	  factors	  or	  non-­‐coding	  RNAs.	  Canonical	   (CBX-­‐containing)	  PRC1	  
complexes	   are	   recruited	   (dashed	   arrow)	   to	   H3K27me3,	   while	   Non-­‐canonical	   (PRC2-­‐independent)	   PRC1	   is	  
recruited	  (dashed	  arrow)	  to	  CpG	  islands	  (blue	  circles)	  by	  KDM2B.	  Both	  CBX-­‐containing	  and	  PRC2-­‐independent	  
PRC1	  complexes	  catalyze	  the	  ubiquitylation	  of	  H2AK119	  (red	  hexagons).	  
	  
Figure	  2.	  Schematic	  representation	  of	  HDAC1/2-­‐containing	  complexes.	  	  
HDAC1/2	  of	  SIN3,	  NuRD	  and	  CoREST	  catalyze	  the	  removal	  of	  acetyl	  groups	  from	  histone	  tails	  (green	  triangles).	  
The	   NuRD	   subunits	   CHD3/4	   are	   ATP-­‐dependent	   chromatin	   remodelers	   and	   LSD1	   present	   in	   CoREST	   (and	  
possibly	  also	  NuRD)	  catalyzes	  demethylation	  of	  H3K4me1/2	  (green	  circles).	  Recruitment	  of	  HDAC1/2-­‐containing	  
complexes	   is	   thought	   to	   rely	   on	   chromatin-­‐binding	   domains	   within	   each	   complex	   or	   additional	   interaction	  
partners	  (not	  depicted).	  
	  
Figure	  3.	  Chromatin	  sets	  thresholds	  for	  gene	  activation	  controlling	  cell	  identity.	  	  
A.	   The	   chromatin	   environment	   sets	   thresholds	   for	   gene	   activation,	   ensuring	   that	   persistent	   exposure	   to	  
appropriate	  signals	  (e.g.	  increasing	  transcription	  factor	  levels)	  is	  required	  for	  transcriptional	  activation.	  Loss	  of	  
chromatin	   repressive	   complexes	   (dashed	   line)	   lowers	   the	   threshold	   and	   increases	   transcriptional	   noise.	   B.	  
Changes	  in	  chromatin	  thresholds	  in	  turn	  alter	  the	  barriers	  against	  changes	  in	  cell	  identity	  mediated	  by	  extrinsic	  
(e.g.	  growth	   factors	  or	  hormones)	  and	   intrinsic	   (e.g.	   transcription	   factor	   levels	  or	  somatic	  mutations)	   signals.	  
The	  biological	   outcome	   (whether	   the	  barriers	   are	   increased	  or	  decreased)	  depends	  on	  which	   genes	  become	  
aberrantly	  activated	  by	  the	  loss	  of	  chromatin	  repressive	  complexes	  (dashed	  lines).	  For	  instance,	  if	  a	  repressive	  
complex	   acts	   to	   limit	   the	   expression	   of	   an	   oncogene,	   loss	   of	   the	   complex	   would	   promote	   oncogenesis.	  
Conversely,	   if	   the	   complex	   binds	   a	   tumor	   suppressor,	   its	   loss	   would	   increase	   the	   barrier	   for	   oncogenic	  
transformation.	  Thus,	  loss	  of	  a	  chromatin	  repressive	  complex	  can	  influence	  cell	  identity	  in	  different	  directions,	  
depending	  on	  the	  genes	  they	  regulate	  and	  the	  integration	  of	  the	  combined	  signals	  the	  affected	  cell	  receives.	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